Mary-Lee Dequeant

Mary-Lee Dequeant is an accomplished executive in the biopharmaceutical sector, currently serving as Executive Director and Head of In Vivo Research at CRISPR Therapeutics since May 2016. With a strong focus on immuno-oncology, Mary-Lee has successfully led the development and approval of Next-Gen CAR-T therapies for both solid and hematological cancers. Prior to this role, Mary-Lee held various positions at CRISPR Therapeutics where contributions included significant advancements in preclinical research and the establishment of robust in vivo pipelines. Mary-Lee's academic background includes a Ph.D. in Developmental Biology and Embryology from the University of Kansas Medical Center, as well as multiple degrees in Biochemistry, Genetics, and Medical Ethics from prestigious institutions. Early research endeavors were shaped at the Stowers Institute and Harvard Medical School, where foundational work on genetic networks and embryonic cell line development took place.